SCHEMBL19783217

SCHEMBL19783217

Cc1cc(O)cc2sc(Cl)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
CHRM1 P11229 1/20 0.43
ALOX15 P16050 1/20 0.43
MAOA P21397 1/20 0.43
TBXA2R P21731 1/20 0.43
ADRA1A P35348 1/20 0.43
HTR2B P41595 1/20 0.43
HSD17B10 Q99714 1/20 0.41
ESR2 Q92731 3/20 0.40
ESR1 P03372 2/20 0.40
ALDH1A1 P00352 5/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 2/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
F2RL3 Q96RI0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189784 1.00 CYP3A4 (0.43) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL13415695 0.81 GAA (0.44) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL1196608 0.81 RAB9A (0.47) ALOX15HSD17B10ALDH1A1MAPTKDM4E
SCHEMBL11337728 0.81 HSD17B10 (0.61) HSD17B10ALDH1A1MAPTKDM4ENPC1
SCHEMBL28814644 0.81 ALDH1A1 (0.43) CYP3A4ALOX15HSD17B10ESR2ESR1
SCHEMBL19782753 0.79 HSD17B10 (0.42) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL8975919 0.78 HSD17B10 (0.41) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL5530542 0.78 HSD17B10 (0.68) CYP3A4HSD17B10ESR2ESR1ALDH1A1
SCHEMBL9306136 0.77 ALDH1A1 (0.57) CYP3A4ESR2ESR1ALDH1A1MAPT
SCHEMBL19782466 0.75 ALDH1A1 (0.46) CYP3A4HSD17B10ALDH1A1KMT2AF2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYP3A4 15/4885CHRM1 690/4885ALOX15 1358/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYP3A4 18/4885CHRM1 687/4885ALOX15 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.